Acute ischemic stroke and COVID-19

Posted November 16, 2020

ABSTRACT
Ischemic stroke may be a presenting feature of COVID-19. Its etiology remains unclear, but severe COVID-19 disease might increase the risk of large-artery strokes. More evidence is needed to substantiate the current reports and provide insights for optimal management.

INTRODUCTION
Although COVID-19 mostly causes lung injury, there are emerging data on related neurologic complications, including acute cerebrovascular disease.

INCIDENCE AND RISK FACTORS
A stroke incidence of 2.5% to 6% has been reported in retrospective studies of European and Chinese hospitalized COVID-19 patients.1-3

In a study of 219 patients hospitalized with COVID-19 in Wuhan, China,4 those with acute stroke (N = 11; 5.0%) were more likely to be older, to present with severe symptoms, to have cardiovascular risk factors, such as hypertension and diabetes, and a history of cerebrovascular disease. In this report, fewer patients developed intracranial hemorrhage (0.5%) than acute ischemic stroke (4.6%).

Acute ischemic stroke was also reported during the earlier severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) epidemics.5,6 Of 206 patients hospitalized for SARS in Singapore, 5 patients (2.4%) had large-artery strokes.5 Three had no traditional cerebrovascular risk factors and 4 were critically ill, suggesting an association with the infection itself or its treatment. Potential causes of acute ischemic stroke in these patients included low ejection fraction from cardiac dysfunction, disseminated intravascular coagulopathy, and marantic (nonbacterial thrombotic) endocarditis.

A recent case series from New York City supports this study’s findings, as large-vessel ischemic strokes occurred in 5 patients with COVID-19 younger than 50 years.7 Each presented with acute stroke symptoms and lymphopenia and elevated inflammatory markers on admission laboratory tests, but 2 had no COVID-19 symptoms.

REVIEW OF PROPOSED ETIOLOGIES
Coagulopathy
Patients with severe COVID-19 symptoms might be at risk of thromboembolic events from coagulopathy associated with COVID-19. In studies, patients hospitalized with COVID-19 have been reported to have increased coagulation activity marked by increased D-dimer concentrations.1-3,8-10 In one study, a D-dimer value greater than 1 μg/mL was associated with fatal outcome of COVID-19.9 In another study, patients with both cerebrovascular disease and SARS-CoV-2 had higher D-dimer levels than SARS-CoV-2 patients without cerebrovascular disease (6.9 mg/L vs 0.5 mg/L, P < .001).4

It remains unclear if elevated D-dimer values in patients with COVID-19 are directly associated with either arterial or venous ischemic stroke, or both. There is only 1 recent report of cerebral venous sinus thrombosis in a patient with severe COVID-19 who was successfully treated with anticoagulants.9

Antiphospholipid antibodies
Lupus anticoagulants and prolonged activated partial thromboplastin time are also frequently found in hospitalized patients with COVID-19, in whom the prevalence of lupus anticoagulant is 45% to 91%.9-12 There is no clear association between lupus anticoagulant and thrombosis in these studies, but a case series reported the finding of antiphospholipid antibodies in 3 critically ill COVID-19 patients with bilateral cerebral infarcts in multiple vascular territories.12 Laboratory investigations showed increased antiphos-
phospholipid antibodies, including anticardiolipin immunoglobulin A (IgA) and beta-2 glycoprotein IgM and IgG, but without lupus anticoagulant.

This case series suggested that an acquired antiphospholipid syndrome was the underlying etiology, but unlike in the series of large-artery strokes in 5 young patients, these patients with antiphospholipid antibodies were over 60 years of age. The study did not provide information on other arterial or venous thromboembolism or report laboratory values for IgM or IgG antiphospholipid antibodies. In addition, 2 patients had prior strokes, but their underlying causes were not discussed. Finally, the questionable association of thrombosis with IgA antiphospholipid makes it difficult to determine a causal relationship.

These reports indicate the presence of antiphospholipid antibodies at variable frequencies, but likely higher than expected in the general population. Because their clinical significance is not yet known, these laboratory tests should not be routinely checked in COVID-19 patients without thrombosis.

Vasculitis
Other etiologies of ischemic stroke, such as virus-induced central nervous system vasculitis, were proposed when MERS and SARS patients had brain lesions in vascular patterns without a clear cerebrovascular cause. Postmortem histologic analysis of 3 patients with COVID-19 revealed lymphocytic endotheliitis within the endothelial cells of multiple organs, including the lungs, heart, kidneys, small intestine, and liver.

The authors reported that endotheliitis may have caused microcirculatory vasoconstriction and endothelial dysfunction with consequent ischemia and apoptosis in the patients. Furthermore, direct viral infection of endothelial cells via angiotensin-converting enzyme 2 receptors, along with the host inflammatory response, may contribute to the wide spectrum of clinical sequelae of COVID-19. Histopathologic analysis of the central nervous system is needed to determine if SARS-CoV-2-related central nervous system vasculitis can occur from lymphocytic endotheliitis.

MANAGEMENT

Standard acute ischemic stroke management should be pursued, including reperfusion therapy with intra-venous alteplase and mechanical thrombectomy.

Imaging findings in patients with COVID-19 with stroke have not revealed a single mechanism with evidence of small-vessel infarction, large-artery strokes, and cardioembolism. In addition, imaging options are likely limited in most patients, given the disease severity and limited access to magnetic resonance imaging (MRI).

One study reported unusual MRI findings in 13 patients with COVID-19 with encephalopathy. Imaging revealed leptomeningeal enhancement in 8 patients, and 3 patients were found to have silent cerebral ischemic strokes. Interestingly, all 11 patients who underwent perfusion imaging showed bilateral frontotemporal hypoperfusion. This study suggests that cerebral ischemia and meningoencephalitis might be underreported in patients with COVID-19 with encephalopathic presentations.

Close monitoring of characteristic laboratory findings of COVID-associated coagulopathy, such as elevated D-dimer and fibrinogen, shortened prothrombin time and augmented partial thromboplastin time, and low international normalized ratio should be considered in suspected COVID-19 cases.

Appropriate diagnostic workup and antiplatelet agents for secondary stroke prevention should be considered.

Although prophylaxis of venous thromboembolism would be recommended for all nonambulatory hospitalized patients with COVID-19, including those with ischemic strokes, therapeutic anticoagulation for prevention of stroke remains uncertain. Current practices encourage an individualized decision based on imaging, timing, clinical context, and risk-benefit discussions.

Management strategies for anticoagulation in stroke patients with COVID-19 may change as more data are published.

DISCLOSURES

Dr. Hassett, Dr. Gedansky, and Dr. Uchino report nothing to disclose. Dr. Mays reported financial interests with Lilly (advisory), Teva, Amgen, Allergan (speaker’s bureau), and DynamedPlus (consultant).

REFERENCES

5. Umapathi T, Kor AC, Venketasubramanian N, et al. Large artery
Correspondence: Ken Uchino, MD, Cerebrovascular Center and Department of Neurology, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; uchinok@ccf.org